Partners and Collaborators

EpiBiome could not harness the power of the microbiome without strong collaboration with partners. Powerful partnerships combine complementary talents, expertise and passion with EpiBiome’s organizational capabilities to deliver innovation that improves the wellbeing of animals, people and the environment globally.

Strong collaboration facilitates ingenuity. EpiBiome’s multidisciplinary team is developing partnerships and collaborations across agribusiness, pharmaceutical, government, academia and animal and human health organizations. Working creatively, we complement our expertise with our partners’ strengths and technologies to achieve even better and more rapid success to benefit all.

Illumina – EpiBiome was accepted into the inaugural class of Illumina Accelerator and maintains a close relationship with the company.

Johnson & Johnson Innovation
Johnson & Johnson Innovation – EpiBiome won Johnson & Johnson Innovation, JLABS’ Quick Fire Challenge, with a prize of one-year of free lab space at JLABS@SSF.

Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) – EpiBiome was accepted into and graduated from the FAST Program.

Springboard Enterprises
Springboard Enterprises – EpiBiome was admitted into the Springboard Accelerator, a program for majority women-owned companies or companies with women in leadership positions.

The Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation – EpiBiome won a Gates Foundation Grand Challenges Explorations Grant for its work on tackling a pathogen that disproportionately affects infants in developing countries.

StartX – EpiBiome was accepted into StartX, Stanford’s stage-agnostic accelerator.

Molecular Foundry
Molecular Foundry – EpiBiome has an active user proposal at the Foundry, giving the company access to millions of dollars in instruments and resources at the DOE-funded facility on the UC Berkeley campus.

BIO – EpiBiome was named the “Buzz of BIO” in the “Technologies of Tomorrow” category and “Best Company Presentation” in the AMR Focus session at BIO2016

SXSW Accelerator – EpiBiome advanced from 480 companies to the final 3 in the SXSW Accelerator at the Interactive Festival.

Ludwik Hirszfeld Institute of Immunology and Experimental Medicine
Ludwik Hirszfeld Institute of Immunology and Experimental Therapy – EpiBiome has an ongoing collaboration with Prof. Andrzej Górski, Head of Phage Therapy Unit and Bacteriophage Laboratory, and Fulbright Scholar who treats human patients with phages under EU compassionate use guidelines at the Hirszfeld Institute in Wrocław, Poland. Through this relationship, EpiBiome gains access to human bacterial isolates before and after phage therapy.

SRI – EpiBiome has an active project with SRI’s Center for Infectious Disease.

Ohio State University
Ohio State University – EpiBiome has an active project with the research group of Prof. Matthew Sullivan, a phage genomics expert.

i-Cultiver – i-Cultiver provides the interpretation and application of EpiBiome’s EpiPhany® results to plant producers. i-Cultiver solves problems for the agricultural industry through translation and field application of basic research.

University of California – Davis – EpiBiome has an active project with the research group of Prof. Maria Marco on microbiome characterization of dairy products